Clarus Therapeutics (CRXT) Misses Q1 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 16, 2022 4:05 PM EDTFirst quarter 2022 net revenue increased 72% year-over-year to $4.0 million
First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year
Conference call and webcast today at 5:15 p.m. ET
NORTHBROOK, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the first quarter of 2022.
We delivered a strong first quarter, as the... More
